Qualification of Drivers; Exemption Requests; Epilepsy and Seizure Disorders, 60606-60607 [E6-17032]
Download as PDF
60606
Federal Register / Vol. 71, No. 198 / Friday, October 13, 2006 / Notices
is listed in the ADDRESSES section.
During the meeting, public oral
comments will be accepted for 45
minutes (2:15 p.m. to 3 p.m.). Individual
comments may be limited depending on
the number of persons who wish to
comment. Oral comments will be
accepted on a first come, first serve
basis as requestors register at the
meeting. The comments must directly
address relevant medical and scientific
issues on the MRB meeting agenda. For
more information, please view the
following Web site: https://
www.fmcsa.dot.gov/mrb.
Issued on: October 6, 2006.
John H. Hill,
Administrator.
[FR Doc. E6–17031 Filed 10–12–06; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2006–24278]
Qualification of Drivers; Exemption
Requests; Epilepsy and Seizure
Disorders
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemptions, request for comments.
ycherry on PROD1PC64 with NOTICES2
AGENCY:
SUMMARY: FMCSA announces receipt of
applications from four individuals for
exemptions from the prohibition against
persons with a clinical diagnosis of
epilepsy (or any other condition which
is likely to cause a loss of consciousness
or any loss of ability to control a
commercial motor vehicle (CMV)),
operating trucks and buses in interstate
commerce. If granted, the exemptions
would enable these individuals with
seizure disorders to operate CMVs in
interstate commerce. All records
associated with these requests are
available in the public docket.
DATES: Comments must be received on
or before November 13, 2006.
ADDRESSES: You may submit comments
identified by Department of
Transportation (DOT) Docket
Management System (DMS) Docket
Number FMCSA–2006–24278 using any
of the following methods:
• Web site: https://dmses.dot.gov.
Follow the instructions for submitting
comments on the DOT electronic docket
site.
• Fax: 1–202–493–2251.
• Mail: Docket Management Facility;
U.S. Department of Transportation, 400
Seventh Street, SW., Nassif Building,
VerDate Aug<31>2005
15:21 Oct 12, 2006
Jkt 211001
Room PL–401, Washington, DC 20590–
0001.
• Hand Delivery: Room PL–401 on
the plaza level of the Nassif Building,
400 Seventh Street, SW., Washington,
DC, between 9 a.m. and 5 p.m., Monday
through Friday, except Federal
Holidays.
• Federal eRulemaking Portal: Go to
https://www.regulations.gov. Follow the
on-line instructions for submitting
comments.
Instructions: All submissions must
include the Agency name and docket
number for this notice. Note that all
comments received will be posted
without change to https://dms.dot.gov,
including any personal information
provided. Please see the Privacy Act
heading below.
Docket: For access to the docket to
read background documents or
comments received, go to https://
dms.dot.gov at any time or Room PL–
401 on the plaza level of the Nassif
Building, 400 Seventh Street, SW.,
Washington, DC, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal holidays. The DMS is available
24 hours each day, 365 days each year.
If you want acknowledgment that we
received your comments, please include
a self-addressed, stamped envelope or
postcard or print the acknowledgement
page that appears after submitting
comments on-line.
Privacy Act: Anyone may search the
electronic form of all comments
received into any of our dockets by the
name of the individual submitting the
comment (or of the person signing the
comment, if submitted on behalf of an
association, business, labor union, etc.).
You may review the DOT’s complete
Privacy Act Statement in the Federal
Register published on April 11, 2000
(65 FR 19477; Apr. 11, 2000). This
information is also available at https://
dms.dot.gov.
Dr.
Mary D. Gunnels, Chief, Physical
Qualifications Division, (202) 366–4001,
maggi.gunnels@dot.gov, FMCSA,
Department of Transportation, 400
Seventh Street, SW., Washington, DC
20590–0001. Office hours are from 8:30
a.m. to 5 p.m., Monday through Friday,
except Federal holidays.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
Background
Under 49 U.S.C. 31315 and 31136(e),
FMCSA may grant an exemption for a 2year period if it finds ‘‘such exemption
would likely achieve a level of safety
that is equivalent to, or greater than, the
level that would be achieved absent
such exemption.’’ The statute also
PO 00000
Frm 00146
Fmt 4703
Sfmt 4703
allows the agency to renew exemptions
at the end of the 2-year period. The
individuals listed in this notice have
recently requested an exemption from
the epilepsy prohibition in 49 CFR
391.41(b)(8), which applies to drivers of
CMVs in interstate commerce. Section
391.41(b)(8) states that a person is
physically qualified to drive a
commercial motor vehicle if that person
has no established medical history or
clinical diagnosis of epilepsy or any
other condition which is likely to cause
the loss of consciousness, or any loss of
ability to control a commercial motor
vehicle.
FMCSA provides medical advisory
criteria for use by medical examiners in
determining whether drivers with
certain medical conditions should be
certified to operate CMVs in interstate
commerce. Currently, FMCSA’s medical
advisory criteria includes a
recommendation that individuals
diagnosed with epilepsy and taking
anticonvulsant medication to reduce the
likelihood of seizures are at high risk for
further episodes and should not be
considered for medical certification.
Drivers diagnosed with epilepsy and
taking anticonvulsant medication which
helps them control their seizures may be
at low risk, however, these individuals
are exposed to conditions which place
them at increased risk for loss of
consciousness and therefore increased
risk for seizure occurrence, and the
acquisition of replacement anti-seizure
medication if drugs are lost or forgotten,
place such individuals at some increase
in risk. These individuals should not be
authorized to drive commercial
vehicles. Drivers diagnosed with
epilepsy, seizure free and off medication
for 10 years may be medically certified
to operate CMVs.
FMCSA further notes that individuals
who experience a single unprovoked
seizure, but do not have epilepsy, per
se, are clearly at a higher risk than the
general population to have further
seizures. Individuals with a single
unprovoked seizure, seizure-free for a 5year period and off medications, should
not be restricted from obtaining a
license to operate a CMV. The history of
the occurrence of febrile seizures in
childhood should not be a restriction to
licensing to operate a CMV. Seizures, in
the context of a systemic metabolic
dysfunction, should not be a primary
reason for restriction from medical
certification to operate a CMV. Any
restriction should be based upon the
risk of recurrence of the primary
condition. There are several conditions
in which the risk for unprovoked
seizures is sufficiently high, even in the
absence of the occurrence of acute
E:\FR\FM\13OCN1.SGM
13OCN1
Federal Register / Vol. 71, No. 198 / Friday, October 13, 2006 / Notices
seizures, that medical certification
should be restricted for variable periods
following these incidents (head injury,
surgical procedures involving dural
penetration, cerebrovascular disease and
infections of the nervous system).
Summary of Applications
Anthony P. Besch
Mr. Besch has a history of epilepsy
since childhood, and he currently uses
anti-seizure medications to prevent
seizures. Mr. Besch does not currently
operate a CMV on public roads. Mr.
Besch has stated in his application that
‘‘there would be no negative impacts on
safety as I am seizure free, have
excellent vision, and reflexes.’’ Mr.
Besch’s physician further states that,
‘‘he does have a history of seizures only
in sleep and none during the day;
therefore, Tony is legally able to drive
due to his seizures being in good
control.’’ Mr. Besch holds a Class A CDL
from Illinois.
ycherry on PROD1PC64 with NOTICES2
Charles D. Gant
15:21 Oct 12, 2006
Mr. Morris is a CMV driver who lost
consciousness while driving on March
20, 2004, and was then hospitalized for
three days. Mr. Morris was examined by
a neurologist while he was hospitalized.
The neurologist determined that he had
experienced a seizure. Mr. Morris was
placed on Carbatrol (an anti-seizure
medication) and subsequently, in
August 2004, a medical examiner
refused to certify him as meeting
FMCSA’s requirements. On September
23, 2004, Mr. Morris consulted another
neurologist and his test results
(Electroencephalography and MRI) were
normal, and he was told to gradually
discontinue the Carbatrol. Mr. Morris
states he has had no additional seizures
after March 20, 2004, and has not taken
Carbatrol since November 1, 2004. Mr.
Morris states that two neurologists have
concluded that his seizures were likely
induced by alcohol. He states that his
medical test results are normal and he
has been seizure free for one year and
three months.
Wayne C. Sorenson
Mr. Gant is a hazardous material (HM)
CMV driver who experienced slurred
speech, drooling and numbness in his
left upper extremity for approximately
15 minutes on August 20, 1999. On
August 23, 1999, he was examined at a
hospital emergency room, and
subsequently referred to a neurologist
who diagnosed him as having a stroke
(cerebrovascular accident). He was
prescribed Coumadin which he stopped
taking against medical advice of the
prescribing physician. On October 1,
2002, his physician reported that Mr.
Gant had a left temporal headache with
a reduction in left visual field, but no
abnormal sensation, numbness,
weakness or loss of speech. On June 27,
2004, ‘‘he awakened with involuntary
movements of his left upper extremity
followed by spastic movements of his
left lower extremity lasting for about 20
minutes.’’ His family physician stated
that this represented his third minor
cerebral vascular accident (CVA) or
‘‘quite probably a seizure’’. The
physician performed Magnetic
Resonance Imaging (MRI) on June 30,
2004 which revealed a subacute CVA in
the right frontoparietal junction. Mr.
Gant was examined by his physician on
February 25, 2005 who diagnosed him
as follows: controlled hypertension;
history of at least three (3) previous
CVAs. He was prescribed Coumadin,
Dilantin (an anti-seizure medication)
and Diovan/Hydrochlorothiazide to
prevent seizures.
VerDate Aug<31>2005
John W. Morris, Jr.
Jkt 211001
Mr. Sorenson is a CMV driver who
completed a commercial driving course
to ensure safe operation of a semi
tractor-trailer and was awarded a
certificate in May 2004. He states that he
had seizures 11 years ago while sleeping
which was the result of an adverse
reaction to medication. He has remained
on Tegretol (an anti-seizure medication)
for the last 11 years, and has maintained
therapeutic levels of the medication
and, subsequently, reports that he has
had no seizures. Mr. Sorenson states
that he has no other diagnosed
conditions, physical or psychological
impairment, no history of strength,
sensory or coordination impairment that
would interfere with safe driving. Mr.
Sorenson indicated that a medical
examiner refused to certify him as
meeting FMCSA’s physical
qualifications requirements because of
the seizures he experienced in 1994 and
because he continues to take antiseizure medication.
These four drivers were not granted
medical certification based on 49 CFR
391.41(b)(8) which states: ‘‘A person has
no established medical history or
clinical diagnosis of epilepsy or other
condition which is likely to cause loss
of consciousness or any loss of ability to
control a commercial vehicle.’’
Request for Comments
In accordance with 49 U.S.C. 31315
and 31136(e), FMCSA requests public
comment from all interested persons on
the exemption applications described in
PO 00000
Frm 00147
Fmt 4703
Sfmt 4703
60607
this Notice. We will consider all
comments received before the close of
business on the closing date indicated
earlier in the Notice.
Issued on: October 3, 2006.
John H. Hill,
Administrator.
[FR Doc. E6–17032 Filed 10–12–06; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Surface Transportation Board
[STB Finance Docket No. 34911]
Montana Rail Link, Inc.—Trackage
Rights Exemption—BNSF Railway
Company
BNSF Railway Company (BNSF) has
agreed to grant overhead trackage
rights 1 to Montana Rail Link, Inc. (MRL)
over BNSF’s rail lines extending from
approximately milepost 51.07 at or near
Garrison, MT, to approximately
milepost 21.5, a location south of Warm
Springs, MT, a distance of
approximately 29.57 miles.
The transaction was scheduled to be
consummated on or before October 2,
2006. The purpose of the trackage rights
is to allow for the movement of
sediment from the Clark Fork River
between Garrison and Missoula, MT
(Milltown Dam Area), near Bonner, MT,
to Opportunity Ponds, MT.
As a condition to this exemption, any
employees affected by the trackage
rights will be protected by the
conditions imposed in Norfolk and
Western Ry. Co.—Trackage Rights—BN,
354 I.C.C. 605 (1978), as modified in
Mendocino Coast Ry., Inc.—Lease and
Operate, 360 I.C.C. 653 (1980).
This notice is filed under 49 CFR
1180.2(d)(7). If the notice contains false
or misleading information, the
exemption is void ab initio. Petitions to
revoke the exemption under 49 U.S.C.
10502(d) may be filed at any time. The
filing of a petition to revoke will not
automatically stay the transaction.
An original and 10 copies of all
pleadings, referring to STB Finance
Docket No. 34911, must be filed with
the Surface Transportation Board, 1925
K Street, NW., Washington, DC 20423–
0001. In addition, a copy of each
pleading must be served on Troy Garris,
1 On September 25, 2006, MRL filed a petition for
exemption in STB Finance Docket No. 34911 (SubNo. 1), Montana Rail Link, Inc.—Trackage Rights
Exemption—BNSF Railway Company, wherein
MRL and BNSF request that the Board permit the
proposed overhead trackage rights arrangement
described in the present proceeding to expire on or
about December 31, 2010. That petition will be
addressed by the Board in a separate decision.
E:\FR\FM\13OCN1.SGM
13OCN1
Agencies
[Federal Register Volume 71, Number 198 (Friday, October 13, 2006)]
[Notices]
[Pages 60606-60607]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-17032]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2006-24278]
Qualification of Drivers; Exemption Requests; Epilepsy and
Seizure Disorders
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of applications for exemptions, request for comments.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces receipt of applications from four individuals
for exemptions from the prohibition against persons with a clinical
diagnosis of epilepsy (or any other condition which is likely to cause
a loss of consciousness or any loss of ability to control a commercial
motor vehicle (CMV)), operating trucks and buses in interstate
commerce. If granted, the exemptions would enable these individuals
with seizure disorders to operate CMVs in interstate commerce. All
records associated with these requests are available in the public
docket.
DATES: Comments must be received on or before November 13, 2006.
ADDRESSES: You may submit comments identified by Department of
Transportation (DOT) Docket Management System (DMS) Docket Number
FMCSA-2006-24278 using any of the following methods:
Web site: https://dmses.dot.gov. Follow the instructions
for submitting comments on the DOT electronic docket site.
Fax: 1-202-493-2251.
Mail: Docket Management Facility; U.S. Department of
Transportation, 400 Seventh Street, SW., Nassif Building, Room PL-401,
Washington, DC 20590-0001.
Hand Delivery: Room PL-401 on the plaza level of the
Nassif Building, 400 Seventh Street, SW., Washington, DC, between 9
a.m. and 5 p.m., Monday through Friday, except Federal Holidays.
Federal eRulemaking Portal: Go to https://
www.regulations.gov. Follow the on-line instructions for submitting
comments.
Instructions: All submissions must include the Agency name and
docket number for this notice. Note that all comments received will be
posted without change to https://dms.dot.gov, including any personal
information provided. Please see the Privacy Act heading below.
Docket: For access to the docket to read background documents or
comments received, go to https://dms.dot.gov at any time or Room PL-401
on the plaza level of the Nassif Building, 400 Seventh Street, SW.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays. The DMS is available 24 hours each day, 365
days each year. If you want acknowledgment that we received your
comments, please include a self-addressed, stamped envelope or postcard
or print the acknowledgement page that appears after submitting
comments on-line.
Privacy Act: Anyone may search the electronic form of all comments
received into any of our dockets by the name of the individual
submitting the comment (or of the person signing the comment, if
submitted on behalf of an association, business, labor union, etc.).
You may review the DOT's complete Privacy Act Statement in the Federal
Register published on April 11, 2000 (65 FR 19477; Apr. 11, 2000). This
information is also available at https://dms.dot.gov.
FOR FURTHER INFORMATION CONTACT: Dr. Mary D. Gunnels, Chief, Physical
Qualifications Division, (202) 366-4001, maggi.gunnels@dot.gov, FMCSA,
Department of Transportation, 400 Seventh Street, SW., Washington, DC
20590-0001. Office hours are from 8:30 a.m. to 5 p.m., Monday through
Friday, except Federal holidays.
SUPPLEMENTARY INFORMATION:
Background
Under 49 U.S.C. 31315 and 31136(e), FMCSA may grant an exemption
for a 2-year period if it finds ``such exemption would likely achieve a
level of safety that is equivalent to, or greater than, the level that
would be achieved absent such exemption.'' The statute also allows the
agency to renew exemptions at the end of the 2-year period. The
individuals listed in this notice have recently requested an exemption
from the epilepsy prohibition in 49 CFR 391.41(b)(8), which applies to
drivers of CMVs in interstate commerce. Section 391.41(b)(8) states
that a person is physically qualified to drive a commercial motor
vehicle if that person has no established medical history or clinical
diagnosis of epilepsy or any other condition which is likely to cause
the loss of consciousness, or any loss of ability to control a
commercial motor vehicle.
FMCSA provides medical advisory criteria for use by medical
examiners in determining whether drivers with certain medical
conditions should be certified to operate CMVs in interstate commerce.
Currently, FMCSA's medical advisory criteria includes a recommendation
that individuals diagnosed with epilepsy and taking anticonvulsant
medication to reduce the likelihood of seizures are at high risk for
further episodes and should not be considered for medical
certification. Drivers diagnosed with epilepsy and taking
anticonvulsant medication which helps them control their seizures may
be at low risk, however, these individuals are exposed to conditions
which place them at increased risk for loss of consciousness and
therefore increased risk for seizure occurrence, and the acquisition of
replacement anti-seizure medication if drugs are lost or forgotten,
place such individuals at some increase in risk. These individuals
should not be authorized to drive commercial vehicles. Drivers
diagnosed with epilepsy, seizure free and off medication for 10 years
may be medically certified to operate CMVs.
FMCSA further notes that individuals who experience a single
unprovoked seizure, but do not have epilepsy, per se, are clearly at a
higher risk than the general population to have further seizures.
Individuals with a single unprovoked seizure, seizure-free for a 5-year
period and off medications, should not be restricted from obtaining a
license to operate a CMV. The history of the occurrence of febrile
seizures in childhood should not be a restriction to licensing to
operate a CMV. Seizures, in the context of a systemic metabolic
dysfunction, should not be a primary reason for restriction from
medical certification to operate a CMV. Any restriction should be based
upon the risk of recurrence of the primary condition. There are several
conditions in which the risk for unprovoked seizures is sufficiently
high, even in the absence of the occurrence of acute
[[Page 60607]]
seizures, that medical certification should be restricted for variable
periods following these incidents (head injury, surgical procedures
involving dural penetration, cerebrovascular disease and infections of
the nervous system).
Summary of Applications
Anthony P. Besch
Mr. Besch has a history of epilepsy since childhood, and he
currently uses anti-seizure medications to prevent seizures. Mr. Besch
does not currently operate a CMV on public roads. Mr. Besch has stated
in his application that ``there would be no negative impacts on safety
as I am seizure free, have excellent vision, and reflexes.'' Mr.
Besch's physician further states that, ``he does have a history of
seizures only in sleep and none during the day; therefore, Tony is
legally able to drive due to his seizures being in good control.'' Mr.
Besch holds a Class A CDL from Illinois.
Charles D. Gant
Mr. Gant is a hazardous material (HM) CMV driver who experienced
slurred speech, drooling and numbness in his left upper extremity for
approximately 15 minutes on August 20, 1999. On August 23, 1999, he was
examined at a hospital emergency room, and subsequently referred to a
neurologist who diagnosed him as having a stroke (cerebrovascular
accident). He was prescribed Coumadin which he stopped taking against
medical advice of the prescribing physician. On October 1, 2002, his
physician reported that Mr. Gant had a left temporal headache with a
reduction in left visual field, but no abnormal sensation, numbness,
weakness or loss of speech. On June 27, 2004, ``he awakened with
involuntary movements of his left upper extremity followed by spastic
movements of his left lower extremity lasting for about 20 minutes.''
His family physician stated that this represented his third minor
cerebral vascular accident (CVA) or ``quite probably a seizure''. The
physician performed Magnetic Resonance Imaging (MRI) on June 30, 2004
which revealed a subacute CVA in the right frontoparietal junction. Mr.
Gant was examined by his physician on February 25, 2005 who diagnosed
him as follows: controlled hypertension; history of at least three (3)
previous CVAs. He was prescribed Coumadin, Dilantin (an anti-seizure
medication) and Diovan/Hydrochlorothiazide to prevent seizures.
John W. Morris, Jr.
Mr. Morris is a CMV driver who lost consciousness while driving on
March 20, 2004, and was then hospitalized for three days. Mr. Morris
was examined by a neurologist while he was hospitalized. The
neurologist determined that he had experienced a seizure. Mr. Morris
was placed on Carbatrol (an anti-seizure medication) and subsequently,
in August 2004, a medical examiner refused to certify him as meeting
FMCSA's requirements. On September 23, 2004, Mr. Morris consulted
another neurologist and his test results (Electroencephalography and
MRI) were normal, and he was told to gradually discontinue the
Carbatrol. Mr. Morris states he has had no additional seizures after
March 20, 2004, and has not taken Carbatrol since November 1, 2004. Mr.
Morris states that two neurologists have concluded that his seizures
were likely induced by alcohol. He states that his medical test results
are normal and he has been seizure free for one year and three months.
Wayne C. Sorenson
Mr. Sorenson is a CMV driver who completed a commercial driving
course to ensure safe operation of a semi tractor-trailer and was
awarded a certificate in May 2004. He states that he had seizures 11
years ago while sleeping which was the result of an adverse reaction to
medication. He has remained on Tegretol (an anti-seizure medication)
for the last 11 years, and has maintained therapeutic levels of the
medication and, subsequently, reports that he has had no seizures. Mr.
Sorenson states that he has no other diagnosed conditions, physical or
psychological impairment, no history of strength, sensory or
coordination impairment that would interfere with safe driving. Mr.
Sorenson indicated that a medical examiner refused to certify him as
meeting FMCSA's physical qualifications requirements because of the
seizures he experienced in 1994 and because he continues to take anti-
seizure medication.
These four drivers were not granted medical certification based on
49 CFR 391.41(b)(8) which states: ``A person has no established medical
history or clinical diagnosis of epilepsy or other condition which is
likely to cause loss of consciousness or any loss of ability to control
a commercial vehicle.''
Request for Comments
In accordance with 49 U.S.C. 31315 and 31136(e), FMCSA requests
public comment from all interested persons on the exemption
applications described in this Notice. We will consider all comments
received before the close of business on the closing date indicated
earlier in the Notice.
Issued on: October 3, 2006.
John H. Hill,
Administrator.
[FR Doc. E6-17032 Filed 10-12-06; 8:45 am]
BILLING CODE 4910-EX-P